

Saif Zaman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6853804/publications.pdf>

Version: 2024-02-01

20
papers

380
citations

840776

11
h-index

839539

18
g-index

20
all docs

20
docs citations

20
times ranked

300
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting Trop-2 in solid tumors: future prospects, OncoTargets and Therapy, 2019, Volume 12, 1781-1790.	2.0	95
2	Recovery of T-cell receptor V(D)J recombination reads from lower grade glioma exome files correlates with reduced survival and advanced cancer grade. Journal of Neuro-Oncology, 2018, 140, 697-704.	2.9	41
3	T-cell receptor CDR3 domain chemical features correlate with survival rates in bladder cancer. Journal of Cancer Research and Clinical Oncology, 2019, 145, 615-623.	2.5	32
4	Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma. Oncogene, 2020, 39, 1773-1783.	5.9	29
5	A scoring system for the electrostatic complementarities of T cell receptors and cancer mutant amino acids: multi-cancer analyses of associated survival rates. Immunology, 2020, 159, 373-383.	4.4	23
6	High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG-PIK3CA interactions and breast cancer. Molecular Immunology, 2021, 135, 247-253.	2.2	22
7	MAPT (Tau) expression is a biomarker for an increased rate of survival for low grade glioma. Oncology Reports, 2019, 41, 1359-1366.	2.6	21
8	MAPT (Tau) expression is a biomarker for an increased rate of survival in pediatric neuroblastoma. Cell Cycle, 2018, 17, 2474-2483.	2.6	19
9	Immune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates. Breast Cancer Research and Treatment, 2019, 173, 167-177.	2.5	18
10	A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2 ⁺ breast cancer. Drug Design, Development and Therapy, 2019, Volume 13, 309-316.	4.3	15
11	Chemical complementarity between immune receptors and cancer mutants, independent of antigen presentation protein binding, is associated with increased survival rates. Translational Oncology, 2021, 14, 101069.	3.7	15
12	Mutant cytoskeletal and ECM peptides sensitive to the ST14 protease are associated with a worse outcome for glioblastoma multiforme. Biochemical and Biophysical Research Communications, 2018, 503, 2218-2225.	2.1	9
13	Systemic Adaptive Immune Parameters Associated with Neuroblastoma Outcomes: the Significance of Gamma-Delta T Cells. Journal of Molecular Neuroscience, 2021, 71, 2393-2404.	2.3	8
14	Potential MMP2-mediated availability of HLA binding, mutant ECM peptides reflects better melanoma survival rates and greater T-cell infiltrates. Laboratory Investigation, 2019, 99, 1287-1295.	3.7	5
15	An age-based, RNA expression paradigm for survival biomarker identification for pediatric neuroblastoma and acute lymphoblastic leukemia. Cancer Cell International, 2019, 19, 73.	4.1	5
16	MMP7 sensitivity of mutant ECM proteins: An indicator of melanoma survival rates and T-cell infiltration. Clinical Biochemistry, 2019, 63, 85-91.	1.9	5
17	Antiviral T Cell Receptor Complementarity Determining Region-3 Sequences Are Associated with a Worse Cancer Outcome: A Pancancer Analysis. Viral Immunology, 2020, 33, 404-412.	1.3	5
18	Specific HLA alleles, paired with TCR V- and J-gene segment usage, link to distinct multiple myeloma survival rates. Leukemia and Lymphoma, 2021, 62, 1711-1720.	1.3	5

#	ARTICLE	IF	CITATIONS
19	Immunogenomics of colorectal adenocarcinoma: Survival distinctions represented by immune receptor, CDR3 chemical features and high expression of BTN gene family members. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100196.	1.7	4
20	TRBV and TRBJ usage, when paired with specific HLA alleles, associates with distinct head and neck cancer survival rates. <i>Human Immunology</i> , 2020, 81, 692-696.	2.4	4